Home >> Signaling Pathways >> Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Products for  Apoptosis

  1. Cat.No. 产品名称 Information
  2. GC91820 PDIC-NS PDIC-NS is an activator of stimulator of interferon genes (STING).
  3. GC91782 DPP-9 Inhibitor 42

    Dipeptidyl Peptidase 9 Inhibitor 42

    DPP-9 inhibitor 42 is an inhibitor of dipeptidyl peptidase 9 (DDP-9; IC50 = 0.0034 µM).
  4. GC91688 PDIC-NN PDIC-NN is an intermediate in the synthesis of PDIC-NS , an activator of stimulator of interferon genes (STING) with anticancer activity.
  5. GC91595 PDIC-NC PDIC-NC is an activator of stimulator of interferon genes (STING) and an anticancer agent.
  6. GC72575 L-Glutamic acid monosodium (hydrate) L-Glutamic acid monosodium (hydrate)是一种营养添加剂和调味剂。
  7. GC72511 L-Cystathionine dihydrochloride L-Cystathionine dihydrochloride是一种非蛋白硫醚,是与含硫氨基酸代谢状态相关的关键氨基酸。
  8. GC72463 Rulonilimab Rulonilimab是一种针对PD-1的人IgG1单克隆抗体,其靶向、结合并抑制PD-1及其下游信号通路。
  9. GC72440 Ozoralizumab Ozoralizumab (ATN-103)是一种抗tnf α人源化抗体。
  10. GC72423 Letolizumab Letolizumab (BMS-986004)是一种靶向CD40L的单克隆抗体,其产生是为了表达缺乏效应功能的突变体IgG1,包括Fc结合和补体固定。
  11. GC72419 Iscalimab Iscalimab(CFZ-533)是一种靶向CD40的非耗竭性IGg1单克隆抗体(KD:0.3nM)。
  12. GC72386 Afelimomab Afelimomab(MAK 195F)是一种抗肿瘤坏死因子F(ab')2单克隆抗体片段。
  13. GC72378 Neihulizumab Neihulizumab(ALTB-168)是一种免疫检查点激动性抗体,与人CD162(PSGL-1)结合,导致活化T细胞下调。
  14. GC72365 Visilizumab Visilizumab(抗人CD3E重组抗体)是一种人源化低Fc受体结合的抗CD3单克隆IgG2抗体。
  15. GC72364 Toralizumab Toralizumab(IDEC-131)是一种针对CD40L(CD154)的人源化单克隆抗体(mAb),由人γ1重链和人κ轻链组成。
  16. GC72360 Ruplizumab Ruplizumab(BG 9588)是一种人源化单克隆抗CD40L(TNF受体)IgG1κ抗体。
  17. GC72359 Quilizumab Quilizumab(抗人NGcGM3重组抗体)是一种人源化IgG1κ单克隆抗体。
  18. GC72337 Anti-Mouse 4-1BB/CD137 Antibody (3H3) Anti-Mouse 4-1BB/CD137 Antibody (3H3)是来源于宿主大鼠的抗小鼠4-1BB IgG2a抗体抑制剂。
  19. GC72319 Atrosab Atrosab是一种人源化IgG1拮抗性抗TNFR1抗体。
  20. GC72318 Tulisokibart Tulisokibart (PRA023)是一种人源化IgG1-κ单克隆抗体,靶向TNFSF15/TL1A。
  21. GC72251 Tripeptide-32 Tripeptide-32是一种具有抗衰老作用的生物活性肽,已被报道用作化妆品成分。
  22. GC72216 (Gly14)-Humanin (human) (acetate) (Gly14)-Humanin (human) (acetate)是Humanin的类似物,其中第14个氨基酸丝氨酸被甘氨酸(Gly)取代。
  23. GC72191 Pep19-2.5 Pep19-2.5是一种合成的抗毒素肽,阻断细胞内内毒素信号级联。
  24. GC72186 WLSEAGPVVTVRALRGTGSW WLSEAGPVVTVRALRGTGSW是一种心肌细胞特异性肽。
  25. GC72183 [D-Leu-4]-OB3 [D-Leu-4]-OB3抑制促炎、增殖和转移基因的表达以及pd - l1的表达。
  26. GC72147 Mca-YVADAP-Lys(Dnp)-OH TFA Mca-YVADAP-Lys(Dnp)-OH TFA是caspase-1和血管紧张素转换酶ACE2的荧光底物。
  27. GC72146 WP9QY TFA WP9QY TFATNF-a拮抗剂是一种生物活性肽。
  28. GC72103 Kp7-6 Kp7-6是一种Fas模拟肽,是一种Fas/FasL拮抗剂。
  29. GC72061 β-Phellandrene β-Phellandrene是从岩骨中获得的。
  30. GC72054 Obovatol Obovatol是一种从厚朴叶中分离出来的联苯醚木脂素。
  31. GC72018 Goniothalamin Goniothalamin(GTN)是一种具有抗癌、抗炎和免疫抑制特性的苯乙烯基内酯。
  32. GC72012 Dehydrocrenatidine Dehydrocrenatidine是一种天然生物碱,是一种特定的JAK抑制剂。
  33. GC72001 Phellamurin Phellamurin是从黄柏叶中提取的一种植物黄酮类苷,具有抑制肠道p -糖蛋白的作用。
  34. GC71968 Celosin K Celosin K(化合物8)可以从青藤种子中分离出来。
  35. GC71915 Tanshinone IIB Tanshinone IIB是丹参的主要活性成分,在亚洲国家被广泛用于中风和冠心病的研究。
  36. GC71833 5-Aminolevulinic acid-d2 hydrochloride 5-Aminolevulinic acid-d2 hydrochloride是氘标记的5-氨基酮戊酸盐酸盐。
  37. GC71632 Meloxicam-d3-1 Meloxicam-d3-1是氘标记的美洛昔康。
  38. GC71624 Ketoprofen-d4 Ketoprofen-d4是氘标记的酮洛芬。
  39. GC71622 Prednisone-d8 Prednisone-d8是氘标记的泼尼松。
  40. GC71617 L-Ascorbic acid-13C-2 L-Ascorbic acid-13C-2是13C标记的L-抗坏血酸。
  41. GC71607 Melatonin-d7 Melatonin-d7是氘标记的褪黑素。
  42. GC71544 Antroquinonol Antroquinonol((+)-Antroquinonol),一种从蘑菇Antrodia camphorata中提取的泛醌衍生物,具有保肝、抗炎和抗癌作用。
  43. GC71541 BMS-561392 formate BMS-561392 formate是BMS-561392的甲酸盐形式。
  44. GC71507 5'-Methylthioadenosine-13C6 5'-Methylthioadenosine-13C6是13C标记的5'-甲硫腺苷。
  45. GC71380 UCB-6876 UCB-6876是一种TNFα抑制剂,与TNF三聚体的不对称晶体形式(KD = 22 μM)结合。
  46. GC71355 Zharp2-1 Zharp2-1是一种口服有效的RIPK2抑制剂,与炎症性肠病(IBD)高度相关。
  47. GC71298 DRI-C21041 (DIEA) DRI-C21041 (DIEA)是CD40/CD40L相互作用抑制剂,IC50为0.31 μM。
  48. GC71258 ASK1-IN-4 ASK1-IN-4(化合物17)是ASK1抑制剂(IC50=0.2μM)。
  49. GC71232 I-152 I-152是含有n -乙酰半胱氨酸(NAC)和半胱胺(MEA)的缀合物。
  50. GC71214 CZL55 CZL55是一种半胱天冬酶-1抑制剂,IC50值为24nM。
  51. GC71180 SZM679 SZM679是一种强效、口服活性和选择性的RIPK1抑制剂,RIPK1和RIPK3的Kd值分别为8.6 nM和>5000 nM。

Items 1 to 50 of 2517 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction